We'll agree to diagree.
Even on a revenue-only basis, you are excluding existing revenues when attempting to make the extrapolation/comparison of Gene revenues to the existing share price. Your existing approach to the assessment remains statistically invalid.
Add to My Watchlist
What is My Watchlist?